Wolfgang Miesbach: Roctavian Experience in Modern Hemophilia Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Flora Peyvandi et al., published in RPTH, adding:
“From a ‘haemophilia‑free mind’ to future‑ready care: why gene therapy treaters’ Roctavian experience still matters.
10 haemophilia gene therapy treaters from Germany, Italy and the United States share their real‑world experience with more than 25 adults with severe haemophilia A who received valoctocogene roxaparvovec (Roctavian):
- How they identify and prepare candidates (AAV5 testing, liver assessment, shared decision‑making)
- How centres and multidisciplinary teams are set up (including hub‑and‑spoke models, telemedicine and social work support)
- What actually happens on ‘infusion day’ and in the weeks afterwards
- How long‑term FVIII and liver monitoring is organised and how ALT rises are managed with steroids.
Why is this still important, even though Roctavian will no longer be available?
- The infrastructure they have built – hub‑and‑spoke networks, remote monitoring and close collaboration with hepatology and psychology – will underpin future programmes.
- Patients’ experiences (freedom from prophylaxis, fewer injections, greater independence, easier travel) and their concerns (FVIII durability, liver health, monitoring burden) offer valuable insights for future gene therapy discussions.
- Their collective message: many perceived barriers (approvals, logistics, training) proved manageable once clear pathways and communication structures were in place.”
Title: Real-world provider experiences with hemophilia A gene therapy: administration of valoctocogene roxaparvovec
Authors: Flora Peyvandi, Robert Klamroth, Johannes Oldenburg, Anita Rajasekhar, Andrea Buxton, Matteo Nicola Dario Di Minno, Saskia Gottstein, Amit Soni, Ezio Zanon, Andrew D. Leavitt
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery